NG2/CSPG4 was first characterized as a high-molecular-weight type 1 membrane proteoglycan in rat in 1981 [35], and then identified with a mouse monoclonal antibody (mAb) on human melanoma cells [36]. Here, CSPG4 is linked to melanoma.